UC Davis Comprehensive Cancer Center is the only National Cancer Institute-designated center serving the Central Valley and inland Northern California, a region of more than 6 million people. Its specialists provide compassionate, comprehensive care for more than 100,000 adults and children every year and access to more than 200 active clinical trials at any given time. Its innovative research program engages more than 240 scientists at UC Davis who work collaboratively to advance discovery of new tools to diagnose and treat cancer. Patients have access to leading-edge care, including immunotherapy and other targeted treatments. Its Office of Community Outreach and Engagement addresses disparities in cancer outcomes across diverse populations, and the cancer center provides comprehensive education and workforce development programs for the next generation of clinicians and scientists. For more information, visit cancer.ucdavis.edu.
April 20, 2023
Video
Shared insight on the combination of gemcitabine, cisplatin, and nivolumab in patients with muscle-invasive bladder cancer in the HCRN GU 16-257 trial.
April 19, 2023
Article
April is Head and Neck Cancer Awareness Month, and a promising new research initiative at UC Davis Comprehensive Cancer Center could lead to a new and far more effective standard of care for this group of cancers.
April 13, 2023
Video
R. Lor Randall, MD, FACS, discusses the investigation of ganitumab plus standard-of-care interval-compressed chemotherapy in a phase 3 trial for newly diagnosed metastatic Ewing sarcoma.
April 13, 2023
Video
Focused discussion on the RETAIN BLADDER study, which explored the option to avoid cystectomy in patients with good response to systemic therapy.
April 13, 2023
Video
Continuing their discussion on adjuvant therapy in in muscle-invasive bladder cancer, panelists identify the utility of minimal residual disease testing.
April 11, 2023
Article
R. Lor Randall, MD, FACS, expands on data from a phase 3 trial evaluating the addition of ganitumab to standard-of-care, interval-compressed chemotherapy, the implications of these results, and how the study could help inform future trials exploring other targeted therapies for the treatment of patients with metastatic Ewing sarcoma.
April 06, 2023
Video
Centering discussion on several clinical trials, key opinion leaders reflect on the role of adjuvant therapy in muscle-invasive bladder cancer.
April 06, 2023
Video
Expert perspectives on the evolving role of neoadjuvant therapy in muscle-invasive bladder cancer (MIBC) with considerations for mainstay regimens.
March 30, 2023
Video
Switching their focus to non-muscle-invasive bladder cancer (NMIBC), panelists identify the treatment armamentarium in this setting.
March 30, 2023
Video
A bird’s eye view of treatment modalities in urothelial carcinoma covering systemic, surgical, and bladder preserving strategies.
March 24, 2023
Video
R. Lor Randall, MD, FACS, discusses the potential symptoms and presentation of mesenchymal chondrosarcoma, as well as highlighted recent case studies that he consulted on for patients with mesenchymal chondrosarcoma.
March 23, 2023
Video
A brief review of sequencing patterns in urothelial carcinoma and the typical number of lines of therapy a patient may receive.
March 23, 2023
Video
A panel of four key opinion leaders share real-world urothelial carcinoma practice patterns at their respective institutions.
March 20, 2023
Video
R. Lor Randall, MD, FACS, discusses, the importance of correctly diagnosing mesenchymal chondrosarcoma.
March 02, 2023
Article
R. Lor Randall, MD, FACS, discusses the presentation and diagnosis of mesenchymal chondrosarcomas, the role of HEY1-NCoA2 gene fusions in the disease, and potential treatment options for this rare subgroup of patients.
March 01, 2023
Article
R. Lor Randall, MD, FACS, discusses how sarcoma experts from around the world connected to collaborate on the ISKS, the importance of identifying and better understanding sarcoma subgroups, and how these findings could inform prescreening for those at risk for the disease.
February 16, 2023
Article
New UC Davis study finds relationship between tumor microbiome and immune system in patients with soft tissue sarcoma.
January 20, 2023
Article
Research conducted by UC Davis Comprehensive Cancer Center and the University of Cincinnati shows that direct oral anti-coagulant drugs are more effective and are more cost-effective than low molecular weight heparin for treating cancer-associated thrombosis.
January 07, 2023
Article
R. Lor Randall, MD, FACS, discusses the outcomes of combining surgery and pexidartinib in patients with tenosynovial giant cell tumors, what investigators still need to learn about sequencing the CSF1R inhibitor around surgery, and what the combination approach could mean for patients with TGCT.
December 25, 2022
Article
Robert Lawrence Randall, MD, FACS, discussed the role of biological reconstructions as well as factors that determine whether a patient would benefit more from the reconstructions or traditional prosthetics known as endoprosthetics.